ADMB-3TMS-PRINACA
From Wikipedia, the free encyclopedia
Jump to navigation
Jump to search
Designer drugTemplate:SHORTDESC:Designer drug
Pharmaceutical compoundTemplate:SHORTDESC:Pharmaceutical compound
| File:ADMB-3TMS-PRINACA structure.png | |
| Identifiers | |
|---|---|
| |
| PubChem CID | |
| E number | {{#property:P628}} |
| CompTox Dashboard (EPA) |
|
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C20H32N4O2Si |
| Molar mass | 388.587 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
ADMB-3TMS-PRINACA (ADB-3TMS-PRINACA) is an indazole-3-carboxamide based synthetic cannabinoid receptor agonist that has been sold as a designer drug, first identified in Germany in March 2023. It is the first designer drug ever reported that contains a silicon atom.[1]
Legality
[edit | edit source]ADMB-3TMS-PRINACA is illegal in Germany and Italy.[2]
See also
[edit | edit source]References
[edit | edit source]| Receptor (ligands) |
| ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Transporter (modulators) |
| ||||||||||||||||||||||||||||||
| Enzyme (modulators) |
| ||||||||||||||||||||||||||||||
| Others |
| ||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||
| Stub icon | This cannabinoid related article is a stub. You can help Wikipedia by expanding it. |
Hidden categories:
- Pages with script errors
- Articles with short description
- Articles with missing files
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without UNII source
- Drugs missing an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- All stub articles